Correction of glycosylated oxyhemoglobin-induced impairment of endothelium-dependent vasodilatation by gliclazide

Journal of Diabetes and its Complications

Volumn 14, Issue 4, 2000, Pages 207-214

  Vallejo, Susana ^a   Angulo, Javier ^a   Peiró, Concepción ^b   Sánchez Ferrer, Alberto ^a   Cercas, Elena ^b   Nevado, Julián ^a   Sánchez Ferrer, Carlos F ^b   Rodríguez Mañas, Leocadio ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Ascorbic acid; Diabetes mellitus; Endothelium; Glibenclamide; Gliclazide; Nitric oxide; Superoxide dismutase

Indexed keywords

AMINOGUANIDINE; ASCORBIC ACID; GLIBENCLAMIDE; GLICLAZIDE; GLYCOSYLATED HEMOGLOBIN; NITRIC OXIDE; OXYHEMOGLOBIN; SUPEROXIDE; SUPEROXIDE DISMUTASE;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM; VASODILATATION;

ACETYLCHOLINE; ANIMALS; AORTA; ENDOTHELIUM, VASCULAR; GLICLAZIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MESENTERIC ARTERIES; MICROCIRCULATION; NITRIC OXIDE; OXYHEMOGLOBINS; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDES; VASODILATION;

EID: 0033821748     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(00)00080-5     Document Type: Conference Paper

References (18)

1. Angulo J., Sánchez-Ferrer C.F., Peiró C., Marín J., Rodríguez-Mañas L. Impairment of endothelium-dependent relaxation by increasing percentages of glycosylated human hemoglobin. Possible mechanisms involved. Hypertension. 28:1996;583-592.
2. Archibald V., Cotter M.A., Keegan A., Cameron N.E. Contraction and relaxation of aortas from diabetic rats: effects of chronic anti-oxidant and aminoguanidine treatment. Naunyn-Schmiedeberg's Arch Pharmacol. 353:1996;584-591.
3. Bouskela E., Cyrino F.Z.G.A., Conde C.M.S., García A.A. Microvascular permeability with sulfonylureas in normal and diabetic hamsters. Metabolism. 46(Suppl 1):1997;26-30.
4. Campbell D.B., Lavielle R., Nathan C. The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res Clin Pract. 14:1991;S21-S36.
5. Crapo J.D., McCord J.M., Fridovich I. Preparation and assay of superoxide dismutases. Methods Enzymol. 53:1978;382-393.
6. Desfaits A.C., Serri O., Renier G. Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL. Metabolism. 46:1997;1150-1156.
7. Edelstein D., Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes. 41:1992;26-29.
8. Jennings P.E., Scott N.A., Saniabadi A.R., Belch J.J.F. Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessments. Metabolism. 41:1992;36-39.
9. Misra H.P., Fridovich I. The generation of superoxide radical during the autooxidation of hemoglobin. J Biol Chem. 247:1972;6960-6962.
10. Mullarkey C.J., Edelstein D., Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun. 173:1990;932-939.
11. Mulvany M.J., Halpern W. Contractile properties of small arterial resistance arteries in spontaneously hypertensive and normotensive rats. Circ Res. 4:1977;19-26.
12. O'Brien R.C., Luo M. The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro. Metabolism. 46(Suppl 1):1997;22-25.
13. Palmer K.J., Brogden R.N. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin dependent diabetes mellitus. Drugs. 46:1993;92-125.
14. Rodríguez-Mañas L., Arribas S., Girón C., Villamor J., Sánchez-Ferrer C.F., Marín J. Interference of glycosylated human hemoglobin with endothelium-dependent responses. Circulation. 88:1993;2111-2116.
15. Sakurai T., Tsuchiya S. Superoxide production from nonenzymatically glycated protein. FEBS Lett. 236:1988;406-410.
16. Scott N.A., Jennings P.E., Brown J., Belch J.J.F. Gliclazide: a free radical scavenger. Eur J Pharmacol. 208:1991;175-177.
17. Vallejo S., Angulo J., Peiró C., Nevado J., Sánchez-Ferrer A., Petidier R., Sánchez-Ferrer C.F., Rodríguez-Mañas L. Highly glycated oxyhaemoglobin impairs nitric oxide relaxations in human mesenteric microvessels. Diabetologia. 43:2000;83-90.
18. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes. 46(Suppl 2):1997;S19-S25.